| Hou, Ming-Chih |
P-HCC, NCT01970748: Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices |
|
|
| Recruiting | 4 | 200 | RoW | Propranolol, Inderal, Cardolol, Esophageal variceal ligation, EVL | Taipei Veterans General Hospital, Taiwan | Bleeding Esophageal Varices, Hepatocellular Carcinoma | 12/23 | 12/25 | | |
CVL NR, NCT06594783: Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders |
|
|
| Not yet recruiting | 4 | 80 | RoW | Carvedilol plus endoscopic variceal ligation, Carvedilol alone | Taipei Veterans General Hospital, Taiwan | Cirrhosis, Esophageal Varices | 10/30 | 10/30 | | |
P-HCC-CVL, NCT06594744: Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC |
|
|
| Not yet recruiting | 4 | 120 | RoW | Endoscopic variceal ligation, Carvedilol | Taipei Veterans General Hospital, Taiwan | Hepatocellular Carcinoma (HCC), Esophageal Varices | 10/30 | 10/30 | | |
NCT01298271: A Randomized Trial of GVS Alone vs. Propranolol |
|
|
| Recruiting | 4 | 120 | RoW | propranolol, Inderal, Cardolol | Taipei Veterans General Hospital, Taiwan | Bleeding Gastric Varices, Liver Cirrhosis | 12/25 | 12/25 | | |
| Recruiting | 4 | 150 | RoW | Ertapenem, Invanz | Taipei Veterans General Hospital, Taiwan | Gastric Varix, Sepsis, Liver Cirrhoses, Fever | 12/30 | 12/30 | | |
| Recruiting | 3 | 60 | RoW | L-menthol, Peppermint oil, Placebo, Olive oil | Taipei Veterans General Hospital, Taiwan | Upper Gastrointestinal Endoscopy | 12/20 | 12/20 | | |
| Hou, Ming |
NCT03998982: Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP |
|
|
| Recruiting | 4 | 30 | RoW | Glycyrrhetinic Acid, Dexamethasone | Shandong University | Immune Thrombocytopenia | 06/21 | 06/21 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT03692754: Atorvastatin in Management of Newly Diagnosed ITP |
|
|
| Not yet recruiting | 2/3 | 30 | RoW | Atorvastatin 20mg, atorvastatin calcium, Atorvastatin 10mg, Dexamethasone | Shandong University | Immune Thrombocytopenia, Purpura, Thrombocytopenic | 12/21 | 12/23 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05023915: A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP |
|
|
| Recruiting | 2 | 106 | RoW | dexamethasone, diammonium glycyrrhizinate enteric-coated capsule | Shandong University | Immune Thrombocytopenia | 08/21 | 07/22 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
NCT05020288: A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP |
|
|
| Not yet recruiting | 2 | 40 | NA | Orelabrutinib, ICP-022 | Shandong University | Immune Thrombocytopenia, Bruton's Tyrosine Kinase | 12/23 | 06/24 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04949009: Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP) |
|
|
| Recruiting | N/A | 400 | RoW | Avatrombopag, Doptelet | Shandong University | Primary Immune Thrombocytopenia | 10/21 | 03/22 | | |
| Chen, Liang-Kung |
| Completed | N/A | 60 | RoW | Bonus Winner Mahjong | National Yang Ming University | Aged | 11/21 | 03/22 | | |
NCT05828134: Enhancing Muscle Health and Metabolism in Pre-frail Middle-aged and Older Adults |
|
|
| Completed | N/A | 100 | RoW | protein-enriched soup | National Yang Ming University, Laurel Enterprises Corporation | Muscle Loss, Muscle Weakness | 01/23 | 01/23 | | |
NCT05828043: Brain Aging: Muscle-to-brain Axis Modulates Physio-cognitive Decline |
|
|
| Completed | N/A | 102 | RoW | Multi-domain intervention | National Yang Ming University, National Science and Technology Council | Age-related Cognitive Decline, Age-related Physiology Decline | 07/23 | 07/23 | | |
| Chen, Chiang-Kung |
| No trials found |
